Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge

Grail shares surged Monday after FDA staff released an executive-summary document ahead of an advisory committee meeting on Galleri, the company's multi-cancer early-detection test. The release is a potentially favorable regulatory catalyst for Grail, although the article provides no details on the FDA staff's conclusions or the timing and outcome of any eventual approval decision.